Stock Symbol BMY: Comprehensive Analysis and Insights

BMY, the stock symbol of Bristol-Myers Squibb, is a well-established pharmaceutical company with a rich history dating back to 1887.

Bristol-Myers Squibb was formed through the merger of two companies, Bristol-Myers and Squibb Corporation, in 1989.

The company has a diverse portfolio of innovative medicines, including cancer treatments, immunoscience therapies, and cardiovascular disease medications.

With a strong presence in the pharmaceutical industry, Bristol-Myers Squibb has established itself as a leader in research and development, with a focus on delivering life-changing medicines to patients worldwide.

Bristol-Myers Squibb's stock has seen a 7.4% increase following FDA recognition of its Alzheimer's drug candidate.

The company is making strides in drug development, particularly with positive news on Alzheimer's and multiple myeloma treatments.

This recognition from the FDA is a significant milestone for the company, and it's no wonder investors are excited about the potential of their Alzheimer's treatment.

Bristol-Myers Squibb is a leading player in the pharmaceutical industry, and their research and development efforts are yielding promising results.

BMY's trailing total returns as of 10/3/2025 are 4.09% higher than the S&P 500 benchmark.

The company has a strong dividend program, with a current dividend yield of 4.09%. This is higher than the industry average, and it's also higher than the company's own history.

Here are some key dividend metrics for BMY:

BMY has also been buying back its own shares, with a 3-year average share buyback ratio of 3.1. This can be a sign of a company's confidence in its own stock.

Bristol Myers Squibb's revenue growth has been a highlight in recent times, with the company reporting year-over-year revenues for 1 quarter straight. In the most recent quarter, Bristol Myers Squibb reported revenues of $12.3B.

The company's share buyback program is also worth noting, as it can have a significant impact on share price and earnings per share. Bristol Myers Squibb Co. does have a share repurchase program in place at this time.

Recommended read: Krugerrand Value by Year

In terms of dividend payments, Bristol Myers Squibb's Board of Directors has declared a quarterly dividend of $0.62 per share on common stock, payable on November 3, 2025, to stockholders of record as of October 3, 2025. This is a notable commitment to its shareholders.

Bristol Myers Squibb's dividend yield is also noteworthy, standing at 4.09%. This means that for every dollar invested in the company, the investor can expect to earn around 4 cents in dividend payments.

Here's a summary of Bristol Myers Squibb's key financial metrics:

These metrics provide a snapshot of Bristol Myers Squibb's financial health and stability, and can be used to inform investment decisions.

The profitability of a company is a crucial aspect of its financial performance. It's a measure of how well a company is generating profits compared to its expenses.

One key indicator of profitability is the Gross Margin percentage, which is 74.91% in this case. This means that for every dollar earned, the company retains 74.91 cents as gross profit.

The Operating Margin percentage is also an important metric, standing at 15.35%. This indicates that after accounting for operating expenses, the company still manages to retain a significant portion of its revenue as operating profit.

However, the Net Margin percentage reveals a different story, with a negative value of -15.3%. This means that the company is actually losing money after deducting all expenses, including taxes and interest.

A positive Free Cash Flow Margin percentage of 29.1% suggests that the company is generating sufficient cash from its operations to cover its investments and meet its financial obligations.

The Return on Equity (ROE) percentage is a measure of how well a company is using shareholders' equity to generate profits. Unfortunately, the ROE percentage in this case is a negative -33.27%, indicating that the company is actually eroding shareholders' value.

The Return on Assets (ROA) percentage is another important metric, standing at -7.66%. This suggests that the company is not generating sufficient profits from its assets to cover its expenses.

The Return on Invested Capital (ROIC) percentage is a measure of how well a company is using its invested capital to generate profits. With a value of 9.22%, the company is at least generating some profits from its invested capital.

Over the past 10 years, the company has been profitable for 9 years, which is a relatively good track record.

Take a look at this: Can Equity Be Negative

As an investor, it's essential to stay informed about the performance and prospects of Bristol Myers Squibb Co. (BMY). Analysts' consensus has a Hold rating for the company, with a price target of $53.00, indicating an estimated upside of 20.56% from its current price of $43.96.

The company's earnings have been a concern, with a year-over-year decline for 1 quarter in a row. In the most recent quarter, BMY reported earnings per share of $0.64.

Cash flow operations have been a bright spot, with projected growth from $11.9B in 2023 to $15.9B in 2025. Free cash flow is also expected to increase, from $10.7B in 2023 to $14.6B in 2025.

Here's a snapshot of BMY's projected cash flow:

Keep in mind that these projections are based on analyst estimates and may not reflect the company's actual performance. It's essential to do your own research and consider multiple sources before making any investment decisions.

Bristol-Myers Squibb is a leading worldwide biopharmaceutical company. Its products focus on oncology, immunology, and cardiovascular conditions.

The company completed its merger with Celgene in November 2019. This significant move has likely impacted the company's market presence and financial performance.

Bristol-Myers Squibb derives close to 70% of its total sales from the US market, showing a higher dependence on the US market than most of its peer group.

Here are some key statistics about the company's market presence:

The liquidity ratio is a crucial metric for any business, indicating its ability to meet short-term financial obligations. A liquidity ratio of 1.24 is considered relatively strong, suggesting that the company can cover its current debts with ease.

The quick ratio, a subset of the liquidity ratio, is a more conservative measure, standing at 1.09. This means that for every dollar of current liabilities, the company has $1.09 in liquid assets.

Cash ratio is a more specific measure, standing at 0.36. This indicates that for every dollar of current liabilities, the company has just 36 cents in cash.

A unique perspective: Ticker Symbol for Dollar Tree

The company's inventory is taking a significant amount of time to turnover, with a days inventory of 88.89. This suggests that the company's inventory management could be improved.

Customers are also taking their time to pay their bills, with a days sales outstanding of 69.53. This can have a negative impact on the company's cash flow.

The company's suppliers are being paid relatively slowly, with a days payable of 103.24. This can lead to strained relationships with suppliers and potentially higher costs.

Here's a summary of the liquidity ratio metrics:

Fair Value is a crucial aspect of stock analysis, and it's essential to understand how to calculate it. According to the consensus of 23 analysts, Bristol Myers Squibb Co. has 20.56% upside to fair value with a price target of $53.00 per share.

The fair value calculation is based on various metrics, including price-to-earnings ratio, price-to-book ratio, and earnings yield. The analysts' consensus is a strong indicator of the stock's potential value.

Bristol Myers Squibb Co.'s current price-to-earnings ratio is 50.62, which is higher than its industry average. However, its price-to-book ratio is 7.01, which is relatively low compared to its peers.

Here's a breakdown of Bristol Myers Squibb Co.'s balance sheet for the past few years:

Research Reports can be a valuable resource for investors looking to make informed decisions. Bristol-Myers Squibb is a biopharmaceutical company that discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders.

One key area of focus for Bristol is immuno-oncology, where the firm is a leader in drug development. This expertise has contributed to the company's success in the US market, where it derives close to 70% of its total sales.

Bristol-Myers Squibb is also a component of the S&P 500, indicating its significant presence in the global market. The company's merger with Celgene in November 2019 has further solidified its position as a leading biopharmaceutical company.

Here are some key facts about Bristol-Myers Squibb's market presence:

These facts demonstrate the company's commitment to innovation and its position as a major player in the biopharmaceutical industry.

Let's dive into the key statistics that can give us a better understanding of the company's performance. Revenue for the company is a staggering $47.4 billion for the trailing twelve months.

The company's earnings per share (EPS) for the same period is -$3.59, indicating a significant loss. This is a key metric to keep in mind when evaluating the company's financial health.

The company has a relatively low beta of 0.26, which means it tends to move less in response to overall market fluctuations. This can be a good thing for investors looking for a more stable investment.

Here are some key statistics to keep in mind:

The company's volatility is relatively high at 30.24%, which can be a concern for investors who prefer more stable investments. The 14-day RSI is currently at 70.4, indicating that the stock may be overbought.

Bristol Myers Squibb Co. has had a rough patch lately, underperforming the S&P 500 by -0.87% over the past 5 trading days.

This suggests that its relative strength compared to the major market average is weak at this time.

If you're looking to compare Bristol Myers Squibb Co. to similar companies, you can select up to 4 stocks that match your criteria.